XML 91 R79.htm IDEA: XBRL DOCUMENT v3.25.3
Segment information - Significant Expenses by Segment (Details)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2025
USD ($)
segment
Sep. 30, 2024
USD ($)
segment
Sep. 30, 2025
USD ($)
segment
Sep. 30, 2024
USD ($)
segment
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]        
Number of operating segments | segment 1 1 1 1
Number of reportable segments | segment     1 1
Total revenues $ 211,007 $ 196,786 $ 1,565,978 $ 593,608
Net income (loss) attributable to common stockholders 15,896 (106,654) 817,609 (297,409)
Income tax (benefit) expense (38,970) 8,663 18,093 28,989
Amortization 7,534 3,036 15,393 57,431
Operating segments | Life Science        
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]        
Total revenues 211,007 196,786 1,565,978 593,608
Cost of product, collaboration and license sales 12,441 3,468 28,241 13,140
Program spend 45,940 51,174 143,803 152,497
Employee costs 64,470 57,801 197,762 181,355
Manufacturing costs 11,048 14,229 45,517 44,635
Administrative costs 18,614 18,719 54,924 54,213
Occupancy costs 7,852 7,855 21,678 27,337
Milestones   50,000   65,000
Other segment items 34,746 100,194 256,444 352,840
Net income (loss) attributable to common stockholders 15,896 (106,654) 817,609 (297,409)
Interest income (19,089) (12,821) (57,325) (34,255)
Interest expense 51,681 54,430 154,367 160,188
Income tax (benefit) expense (38,970) 8,663 18,093 28,989
Depreciation 3,569 3,468 10,600 11,489
Amortization 7,534 3,036 15,393 57,431
All other 30,021 43,418 115,316 128,998
Total other segment items $ 34,746 $ 100,194 $ 256,444 $ 352,840